Necitumumab for the treatment of squamous cell non-small cell lung cancer.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 37, doi. 10.1177/1078155216682365
- By:
- Publication type:
- Article
Works matching IS 10781552 AND DT 2018 AND VI 24 AND IP 1
Results: 14
1
2
Clinical effectiveness of bevacizumab in patients with recurrent brain tumours: A population-based evaluation.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 33, doi. 10.1177/1078155216681191
- By:
- Publication type:
- Article
3
Lenvatinib – A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 28, doi. 10.1177/1078155216680119
- By:
- Publication type:
- Article
4
Systemic hypersensitivity to fosaprepitant – A report of two cases.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 76, doi. 10.1177/1078155216680118
- By:
- Publication type:
- Article
5
Cost savings analysis and toxicity audit of a bevacizumab dose rounding policy at a community cancer center.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 42, doi. 10.1177/1078155216675517
- By:
- Publication type:
- Article
6
Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 56, doi. 10.1177/1078155216673229
- By:
- Publication type:
- Article
7
Failure to achieve therapeutic levels with high-dose posaconazole tablets potentially due to enhanced clearance.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 63, doi. 10.1177/1078155216673228
- By:
- Publication type:
- Article
8
Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 3, doi. 10.1177/1078155216671189
- By:
- Publication type:
- Article
9
Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 22, doi. 10.1177/1078155216679025
- By:
- Publication type:
- Article
10
Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 47, doi. 10.1177/1078155216675518
- By:
- Publication type:
- Article
11
Development of a systematic approach to pharmaceutical industry’s patient assistance programs on accessing unfunded cancer drugs.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 18, doi. 10.1177/1078155216677854
- By:
- Publication type:
- Article
12
Supratherapeutic INR resulting from the initiation of warfarin in a patient receiving axitinib.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 74, doi. 10.1177/1078155216677853
- By:
- Publication type:
- Article
13
Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 67, doi. 10.1177/1078155216676633
- By:
- Publication type:
- Article
14
Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 1, p. 9, doi. 10.1177/1078155216676632
- By:
- Publication type:
- Article